HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Mechanistic aspects of inducible nitric oxide synthase-induced lung injury in burn trauma.

AbstractINTRODUCTION:
Although the beneficial effects of inducible nitric oxide synthase (iNOS) inhibition in acute lung injury secondary to cutaneous burn and smoke inhalation were previously demonstrated, the mechanistic aspects are not completely understood. The objective of the present study is to describe the mechanism(s) underlying these favourable effects. We hypothesised that iNOS inhibition prevents formation of excessive reactive nitrogen species and attenuates the activation of poly(ADP) (poly(adenosine diphosphate)) ribose polymerase, thus mitigating the severity of acute lung injury in sheep subjected to combined burn and smoke inhalation.
METHODS:
Adult ewes were chronically instrumented for a 24-h study and allocated to groups: sham: not injured, not treated, n = 6; control: injured, not treated, n = 6; and BBS-2: injured treated with iNOS dimerisation inhibitor BBS-2, n = 6. Control and BBS-2 groups received 40% total body surface area 3rd-degree cutaneous burn and cotton smoke insufflation into the lungs under isoflurane anaesthesia.
RESULTS:
Treatment with iNOS inhibitor BBS-2 significantly improved pulmonary gas exchange (partial pressure of oxygen in the blood/fraction of inspired oxygen (PaO₂/FiO₂) 409 ± 43 mmHg vs. 233 ± 50 mmHg in controls, p < 0.05) and reduced airway pressures (peak pressure 20 ± 1 cm H₂O vs. 28 ± 2 cm H₂O in controls, p < 0.05) and lung water content (lung wet-to-dry ratio 4.1 ± 0.3 vs. 5.2 ± 0.2 in controls, p < 0.05) 24h after the burn and smoke injury. BBS-2 significantly reduced the increases in lung lymph nitrite/nitrate (10 ± 3 μM vs. 26 ± 6 μM in controls, p < 0.05) and 3-nitrotyrosine (109 ± 11 (densitometry value) vs. 151 ± 18 in controls, p < 0.05). Burn/smoke-induced increases in lung tissue nitrite/nitrate, poly(ADP)ribose polymerase, nuclear factor-κB (NF-κB) activity, myeloperoxidase activity and malondialdehyde formation and interleukin (IL)-8 expression were also attenuated with BBS-2.
CONCLUSIONS:
The results provide strong evidence that BBS-2 ameliorated acute lung injury by inhibiting the inducible nitric oxide synthase/reactive nitrogen species/poly(ADP-ribose) polymerase (iNOS/RNS/PARP) pathway.
AuthorsPerenlei Enkhbaatar, Jianpu Wang, Fiona Saunders, Matthias Lange, Atsumori Hamahata, Sebastian Rehberg, John F Parkinson, Lillian D Traber, David N Herndon, Daniel L Traber
JournalBurns : journal of the International Society for Burn Injuries (Burns) Vol. 37 Issue 4 Pg. 638-45 (Jun 2011) ISSN: 1879-1409 [Electronic] Netherlands
PMID21334141 (Publication Type: Journal Article)
CopyrightCopyright © 2011. Published by Elsevier Ltd.
Chemical References
  • Imidazoles
  • Interleukin-8
  • N-((1,3-benzodioxol-5-yl)methyl)-1-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)-4-(methoxycarbonyl)piperazine-2-acetamide
  • NF-kappa B
  • Piperazines
  • Pyrimidines
  • RNA, Messenger
  • 3-nitrotyrosine
  • Tyrosine
  • Malondialdehyde
  • Peroxidase
  • Nitric Oxide Synthase Type II
Topics
  • Analysis of Variance
  • Animals
  • Burns (drug therapy, physiopathology)
  • Disease Models, Animal
  • Female
  • Imidazoles (therapeutic use)
  • Immunohistochemistry
  • Interleukin-8 (metabolism)
  • Lung (metabolism, pathology)
  • Malondialdehyde (metabolism)
  • NF-kappa B (metabolism)
  • Nitric Oxide Synthase Type II (antagonists & inhibitors)
  • Peroxidase (metabolism)
  • Piperazines (therapeutic use)
  • Pulmonary Gas Exchange (drug effects)
  • Pyrimidines (therapeutic use)
  • RNA, Messenger (metabolism)
  • Sheep
  • Smoke Inhalation Injury (drug therapy, physiopathology)
  • Tyrosine (analogs & derivatives, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: